TABLE 5

PK properties observed in in vivo studies with maribavir in cynomolgus monkeys and estimated from the semi-PBPK model. The fm(Gluc) was set as 0.728 unless specified otherwise. The twice-daily doses were administered 8 hours apart within each dosing day

PK Properties on Maribavir in PlasmaObserved, Mean ± S.D.Estimated/Predicted by Semi-PBPK Model
13 mg/kg 14C-Maribavir Intravenous Bolus, Single Dose
AUC0–t (mg·h/l)17.4 ± 3.912.5 (fm(Gluc) = 0.728)
15.1 (fm(Gluc) = 0.853)
CL (l/h)2.99 ± 0.734.02 (fm(Gluc) = 0.728)
3.33 (fm(Gluc) = 0.853)
Vss (l)35.4 ± 6.535.2 (fm(Gluc) = 0.728)
45.8 (fm(Gluc) = 0.853)
5 mg/kg Maribavir Intravenous Bolus, Single Dose
AUC0–t (mg·h/l)4.55 ± 0.715.05
CL (l/h)4.47 ± 0.184.06
Vss (l)36.8 ± 14.735.4
10 mg/kg Maribavir Oral Gavage, Single Dose
AUC0–t (mg·h/l)6.13 ± 3.66.21
Cmax (mg/l)1.50 ± 1.01.01
Tmax (h)2 ± 01.31
F0.661 ± 0.330.615
FaN/A0.671
10 mg/kg Twice-Daily Maribavir Oral Gavage, Multiple Dose
AUC (mg·h/l), day 2, 0–8 h3.60 ± 1.24.41
Cmax (mg/l), day 2, 0–8 h0.97 ± 0.391.13
AUC (mg·h/l), day 27, 0–8 h4.60 ± 0.334.83
Cmax (mg/l), day 27, 0–8 h0.90 ± 0.051.20
30 mg/kg Twice-Daily Maribavir Oral Gavage, Multiple Dose
AUC (mg·h/l), day 2, 0–8 h8.70 ± 1.213.2
Cmax (mg/l), day 2, 0–8 h2.55 ± 0.633.40
AUC (mg·h/l), day 27, 0–8 h12.8 ± 1.414.5
Cmax (mg/l), day 27, 0–8 h2.63 ± 0.383.59
90 mg/kg Twice-Daily Maribavir Oral Gavage, Multiple Dose
AUC (mg·h/l), day 2, 0–8 h32.1 ± 1139.7
Cmax (mg/l), day 2, 0–8 h7.3 ± 3.510.2
AUC (mg·h/l), day 27, 0–8 h30.6 ± 3.243.5
Cmax (mg/l), day 27, 0–8 h6.9 ± 1.110.8
  • AUC0–t, area under the conc.-time curve from time 0 to the last measurable time point; CL, clearance; F, bioavailability; Fa, fraction absorbed; N/A, not available; Tmax, time to peak conc.; Vss, volume of distribution at steady state.